Dextrorphan is a dextrorotatory morphinan and a noncompetitive N-methyl-o-aspartate (NMDA) re ceptor antagonist. We studied the dose response charac teristics of dextrorphan' s neuroprotective efficacy and side effects, correlating these beneficial and adverse re sponses with plasma and brain levels in a rabbit model of transient focal cerebral ischemia. Thirty-three rabbits, anesthetized with halothane, underwent occlusion of the left internal carotid and anterior cerebral arteries for 1 h, followed by 4. 5 h of reperfusion. One hour after the onset of ischemia, they were treated with an i. v. infusion of varying dextrorphan doses or normal saline. After killing, the brains were analyzed for ischemic high signal inten sity using magnetic resonance imaging (MRI) and for ischemic neuronal damage with histopathology. A sepa rate group of 12 anesthetized ischemic rabbits received similar doses of dextrorphan, correlating plasma with brain dextrorphan levels. Twenty-six additional dextror phan unanesthetized, nonischemic rabbits received infu sions of dextrorphan to correlate behavioral side effects with dextrorphan dose and levels. Compared with con trols, the dextrorphan 15 mg/kg group had significantly less cortical ischemic neuronal damage (5. 3 versus 33.2%, p = 0.01) and a reduction in cortical MRI high signal area (9.1 versus 41.2%, p = 0.02). The dextrorphan 10 mg/kg Dextrorphan (D-3-hydroxy-N-methyl-morphinan) is a dextrorotatory morphinan and a noncompeti tive N-methyl-D-aspartate (NMDA) receptor antag onist (Benson et a!.
rabbits showed less cortical ischemic neuronal damage (27.2%) and less MRI high signal (34.8%) but this was not statistically significant (p = 0.6). Dextrorphan 5 mg/kg had no benefit on either neocortical ischemic neuronal damage (35.8%) or MRI high signal (42.9%). The protec tive effect of dextrorphan was correlated with plasma free dextrorphan levels (r = -0.50, p < 0.02 for ischemic neuronal damage; r = -0.66, p < 0. 001 for ischemic MRI high signal). All the rabbits with plasma levels >2,000 ng/ml had <12% cortical ischemic neuronal damage and <34% MRI high signal. All rabbits with plasma levels >3,000 ng/ml showed <7% ischemic neuronal damage and <11% MRI high signal. Plasma levels of -2,500 ng! ml correlated with brain dextrorphan levels of -6,000 ng/g. Unanesthetized rabbits with plasma levels of -2,500 ng/ml demonstrated loss of the righting reflex. These results demonstrate that systemic treatment with dextrorphan after 1 h focal ischemia can significantly pro tect against cerebral damage if adequate plasma and brain levels of dextrorphan are achieved. The brain levels nec essary to obtain in vivo protection are similar to concen trations that prevent glutamate or NMDA-induced injury in neuronal culture. Key Words: Ischemia-Dex trorphan-N-methyl-o-aspartate-Excitotoxicity Cerebrovascular disease-Magnetic resonance imaging.
1987; Lodge et a!. , 1987) . It has been previously shown that dextrorphan attenuates hypoxic neuro nal injury in culture (Goldberg et a!. , 1987) and that high doses of systemic dextrorphan can protect against cerebral damage in rabbit and rat models of focal cerebral ischemia (Steinberg et a!. , 1989a,b; Kent et a!. , 1989; Swan and Meldrum, 1990) . Since dextrorphan is known to block NMDA or gluta mate-induced injury in neuronal culture with a well defined dose response curve (Choi, 1987) , it has been hypothesized that dextrorphan's in vivo pro tection after ischemia is secondary to antagonism of neuronal NMDA receptors (Steinberg et aI. , 1989a,b; Kent et aI. , 1989; Swan and Meldrum, 1990) . However, dextrorphan also blocks voltage dependent calcium channels (Carpenter et aI. , 1988; Jaffe et aI. , 1989) and may have other effects on collateral blood flow, metabolism, or systemic pa rameters, raising the possibility that its protective benefit may also be mediated by non-NMDA mech anisms (Buchan, 1990) .
If protection against ischemic injury in animal models were secondary to neuronal NMDA antag onism, one might expect similar dose-response properties in vivo compared with in vitro data. There is also concern that the high doses of sys temic dextrorphan and other noncompetitive NMDA antagonists such as MK80 1 or ketamine, may cause adverse neurological effects in unanes thetized animals (gait and truncal ataxia, loss of postural reflexes) that might limit their usefulness as neuroprotective agents (Engber and Chase, 1988; Marquis et aI. , 1989; Koek and Colpaert, 1990) . This study was designed to determine the dose response characteristics of dextrorphan's neuropro tective efficacy and side effects, and to correlate these beneficial and adverse responses with plasma and brain levels in a rabbit model of transient, focal ischemia (Steinberg et aI. , 1988 (Steinberg et aI. , , 1989a . Portions of this work were reported in abstract form (Stein berg et aI. , 1989c) .
MATERIALS AND METHODS
Thirty-three male New Zealand white rabbits (2.5-3.5 kg) were sedated and anesthetized with 3% halothane de livered by mask. A femoral arterial catheter and an ear vein catheter were placed and the animals underwent tra cheostomy. Artificial ventilation and anesthesia were maintained using 0.5% halothane in 100% oxygen and a Harvard small-animal ventilator. The animals were ini tially paralyzed with i.v. pancuronium bromide (0.1 mg/ kg) and given additional doses of i.v. pancuronium bro mide (0.05 mg/kg) as necessary to maintain paralysis. Rabbits underwent transorbital clip occlusion of the left internal carotid artery and left anterior cerebral artery for I h, followed by 4.5 h of reperfusion (Steinberg et aI., 1988 (Steinberg et aI., , 1989a . One hour after the onset of ischemia, im mediately after removing the clips, animals were blindly treated i. v. with 15 mg/kg loading dose followed by 15 mg/kg/h of dextrorphan (n = 7), 10 mg/kg loading dose followed by 10 mg/kg/h of dextrorphan (n = 10), 5 mg/kg loading dose followed by 5 mg/kg/h of dextrorphan (n = 8) or an equivalent volume of normal saline (NS) alone (n = 8). The loading dose was given over 30 min. Systemic parameters including rectal temperature, MABP, heart rate, and end-expired CO2 (Puritan-Bennett capnograph) were continuously monitored. Rectal temperature was maintained at 37.5-39.0°C with a warming blanket, MABP kept at 65-75 mm Hg using small boluses of NS if necessary, and end-expired CO2 maintained at 35-40 mm Hg by adjusting the respiratory rate. Arterial blood gases J Cereb Blood Flow Metab, Vol. 11, No.6, 1991 and hematocrit were measured during the experiment and base deficit corrected as necessary with i. v. sodium bi carbonate. Blood samples for dextrorphan levels were drawn in some animals following the loading dose and 2.5 h after the maintenance dose was begun. These samples were centrifuged for 10 min at 2,500 rpm and the plasma frozen and stored at -70°C for later measurement of de x trorphan levels.
After 4.5 h of reperfusion, rabbits were administered a lethal dose of i.v. sodium pentobarbital (100 mg/kg) and perfused transcardially, through a left ventriculostomy with clamping of the descending aorta and opening of the right atrium. A gravity perfusion delivery apparatus was used with the perfusion bottle fixed at a height of 120 cm above the animal's heart (perfusion pressure at heart of 100 mm Hg). Normal saline (300 cc) was perfused fol lowed by 300 cc of 10% buffered formalin (pH 7.4) . In all animals a satisfactory perfusion-fixation was confirmed by clearing of blood from the right eye and rigidity of the neck and forepaws. To avoid postmortem "dark" cell artifact (Cammermeyer, 1961) , the perfused brains were left in the skull in formalin overnight, then removed and fixed an additional 4-6 days in formalin.
Magnetic resonance imaging
The intact fixed brains were evaluated with magnetic resonance imaging (MRI) using a 1.5 Tesla General Elec tric Sigma system having a 6-in diameter saddle coil po sitioned at magnetic isocenter, a 16-cm field of view, a 256 x 256 matrix (0.625 mm pixel diameter), and two excitations/projection (17 min, 10 sec scan time). We ob tained 3-mm-thick, spin-echo, T2-weighted images, using a repetition time of 2,500 msec and an echo time of 80 msec (Steinberg et aI., 1988) . MRI studies of 15 rabbits with similar ischemic lesions in our laboratory have dem onstrated no statistically significant differences in relative signal intensity or area between premortem and postfix ation images, with overlap values of 80-85% (DeLaPaz et aI., 1991) . MRI is a sensitive measure of early cerebral ischemia and the high-intensity signal on T2-weighted im ages likely represents an increase in the water content of ischemic brain (Kato et aI., 1985 (Kato et aI., , 1986 Brandt-Zawadzki et aI., 1986; Horikawa et aI., 1986; Bose et aI., 1988) .
Two standard coronal scans (at the level of the anterior commissure and the level of the optic chiasm) were ana lyzed. The areas of high intensity MRI signal were delin eated by projecting the MRI scans with a standard dark room enlarger onto a transparency. Using an electromag netic digitizing tablet (J andel Scientific Sigma-Scan measurement system) and an IBM PC XT computer, the areas of high intensity signal were measured and ex pressed as a percentage of the total area of left cortex for each coronal level. An average percentage of MRI high signal for each animal was calculated as the total area of high signal for both coronal levels divided by the total area of cortex for both coronal levels (Steinberg et aI., 1988 (Steinberg et aI., , 1989a .
Histopathology
Brains were processed for paraffin embedding, cut at 6 /l-m and stained with hematoxylin and eosin. Ischemic neuronal damage was evaluated by light microscopic ex amination of two standard, coronal sections (3 mm ante rior to the anterior commissure and at the level of the anterior commissure). Early, ischemic neuronal damage was defined as neurons showing moderate to severe shrinkage, increased nuclear basophilia, and a shrunken or pyknotic nucleus. These histological criteria have been used previously to characterize severely injured, isch emic neurons (Brierley, 1973; Garcia and Kamijyo, 1974; Little et aI., 1974; Ginsberg et al., 1979; Tamura et al., 1980; Steinberg et aI., 1986 Steinberg et aI., , 1988 Steinberg et aI., , 1989a .
A tracing of the microscopic section, including bound aries of cortex and striatum, was made on a transparency by projection of the microscope slide with a darkroom enlarger using microscopic examination at x 40-200. All areas containing neurons with ischemic neuronal damage in the cortex and striatum were delineated on the corre sponding transparency. We did not observe ischemic neu rons outside the distribution supplied by the occluded vessels (anterior portion of the middle cerebral artery ter ritory). "Dark" cells of Cammermeyer (1961) were also not observed in the brains, confirming adequate perfu sion-fixation. Using an electromagnetic digitizing tablet (Jandel Scientific Sigma-Scan measurement system) and IBM PC XT computer, the areas of ischemic neuronal damage within the left cortex or left striatum were mea sured and expressed as a percentage of the total area for these corresponding structures. An average percentage area of cortical or striatal ischemic neuronal damage for each animal was calculated as the total area of left cortical or left striatal ischemic neuronal damage for both coronal levels divided by the total area of left cortex or left stri atum for both coronal levels (Steinberg et al., 1988 (Steinberg et al., , 1989a .
Plasma and brain dextrorphan levels
In order to correlate brain dextrorphan levels with postloading dose plasma dextrorphan levels, an addi tional 12 rabbits were anesthetized and underwent two vessel arterial occlusions as described above. One hour after the onset of ischemia, after removing the clips, an imals were treated i. v. over 30 min with 15 mg/kg dex trorphan (n = 4), 10 mg/kg dextrorphan (n = 4), or 5 mg/kg dextrorphan (n = 4). At the termination of the 30 min drug infusion, blood samples for dextrorphan were drawn, frozen, and the rabbits immediately killed with a lethal dose of i.v. sodium pentobarbital (100 mg/kg). The brains were removed fresh and dissected into 16 separate brain regions: left and right cerebellum, left and right thal amus, left and right striatum, left and right hippocampus, left and right frontal cortex, left and right parietal cortex, left and right occipital cortex, and left and right temporal cortex. These samples were frozen and kept at -70°C for later measurement of dextrorphan levels.
To evaluate adverse neurological effects of dextror phan administration, a separate series of unanesthetized rabbits underwent placement of an ear i.v. catheter (using 0.5% xylocaine as local anesthetic) and received varying doses of i. v. dextrorphan as follows: 1) dextrorphan 15 mg/kg loading dose followed by 15 mg/kg/h for 4 h (n = 7); 2) dextrorphan 10 mg/kg loading dose followed by 10 mg/kg/h for 4 h (n = 5); 3) dextrorphan 5 mg/kg loading dose followed by 5 mg/kg/h for 4 h (n = 9); 4) dextrorphan 15 mg/kg loading dose followed by 15 mg/kg/h for 4 h, followed by no infusion of drug for 2 h (n = 5). Rabbits were observed during the entire dextrorphan infusion pe riod for behavioral effects and then killed with 100 mg/kg i. v. of sodium phenobarbital. Blood samples for plasma dextrorphan levels were drawn at the time of death. The brain was removed fresh and separated into cortex, stri atum/thalamus, hippocampus, and cerebellum. These samples were frozen and kept at -70°C for later mea surement of dextrorphan levels. Plasma and brain de x trorphan levels (free dextrorphan and conjugated dextror phan) were determined by Hazelton Laboratories (Mad ison, Wisconsin, U.S.A.) using a standard, high pressure liquid-chromatography method (East and Dye, 1985) .
Statistical analyses
Statistical analyses utilized Kruskal-Wallis Tests, two way Mann-Whitney U tests and linear correlations. All values are given as mean ±SD, p values <0.05 were con sidered significant.
RESULTS

Systemic parameters
There were no differences between groups in sys temic parameters including the temperature, MABP, Paco2, pH, hematocrit, or volume of i.v. fluid infused before arterial occlusion, during occlu sion, or during reperfusion. During occlusion the dextrorphan 15 mg/kg group had a P a02 11.5% higher than the NS group (p < 0.05), and 9% higher than the 10 mg/kg or 5 mg/kg groups (p < 0.05), but all groups had mean P a o2s ranging from 511-578 mm Hg and all rabbits had P a02s of 413-605 mm Hg. P a02 before arterial occlusion did not differ between groups (Table 1) .
Histopathology
The area of neocortical ischemic neuronal dam age ( Fig. 1 ) was significantly reduced in the dextror phan 15 mg/kg group (5.3%) compared with the NS controls (33.2%, p = 0.01). This high dose group Cortex Striatum also showed less neocortical ischemic neuronal damage than the two lower doses of dextrorphan (p = 0.02 versus 5 mg/kg; p = 0. 16 versus 10 mg/kg). The dextrorphan 10 mg/kg rabbits demonstrated less neocortical ischemic neuronal damage (27.2%) than controls, but this did not reach statistical sig nificance (p = 0.6). There was no benefit on isch emic neuronal damage in the dextrorphan 5 mg/kg group (35.8%, p = 0.9). There was no difference in striatal ischemic neuronal damage between any groups (p > 0.9; see Fig. 1 ). MRI MRI (Fig. 2 ) demonstrated significantly smaller areas of cortical high intensity signal in the dextror phan 15 mg/kg group (9. 1%) compared with the NS rabbits (4 1.2%, p = 0.02). The reduction in cortical MRI high signal area shown in this high dose dex trorphan group was also significantly different from the 10 mg/kg (p = 0.005) and 5 mg/kg groups (p = 0.02). Dextrorphan 10 mg/kg reduced the cortical area of MRI high signal (34.8%) compared with con trols, but this was not statistically significant (p = 0.6). Dextrorphan 5 mg/kg had no benefit on MRI high signal area (42.9%, p = 0.9).
Neuroprotection correlated with dextrorphan levels
Rabbits receiving the same dose of dextrorphan showed a wide variation in plasma and brain free dextrorphan levels (see Figs. 3-5 ). The protective effect against both ischemic neuronal damage and ischemic MRI high signal was found to be corre lated with postloading dose plasma free dextror ph an levels (linear correlation for neocortical isch emic neuronal damage versus dextrorphan level, r = -0.50, p < 0.02; MRI high intensity versus dex trorphan level r = -0.66, p < 0.001; see Figs. 3 and 4). All rabbits with postloading dose free dextror- phan levels >2,000 ng/ml had < 12% cortical neuro nal damage and <34% cortical ischemic MRI high signal area. All rabbits with free dextrorphan levels >3,000 ng/ml showed <7% cortical neuronal injury and < 11 % MRI high signal. Rabbits with dextror phan levels >2,000 ng/ml showed 88% reduction in cortical ischemic neuronal damage (p < 0.001) and 76% reduction in ischemic MRI injury ( p < 0.001) compared with rabbits having dextrorphan levels <2,000 ng/ml. Mid-maintenance free dextrorphan levels were also correlated with a protective effect against cortical ischemic neuronal damage and MRI high signal, but this correlation was not as strong as for postloading dose dextrorphan levels (ischemic neuronal damage versus mid-maintenance dextror phan levels r = -0.44, P < 0.05; MRI high signal versus mid-maintenance dextrorphan levels r = -0.57; p < 0.01). Conjugated dextrorphan plasma levels (dextrorphan-glucoronide) were generally 100 0 80 Plasma DX Levels (ng/ml) 4-10 times the free dextrorphan plasma levels. Free dextrorphan was concentrated 2-3 times in brain compared with plasma, and brain free dextrorphan levels were highly correlated with plasma free dex trorphan levels in all cerebral areas examined (Fig.  5 ). Within individual animals brain dextrorphan lev els were not significantly different in ischemic areas (e.g., left frontal cortex, left temporal cortex, left striatum) compared with nonischemic areas, or in regions known to have higher density of NMDA receptors (e.g., hippocampus, cortex) compared with regions having a lower density of these recep tors (Fig. 5 ). There was no correlation between in traischemic rectal temperature and area of ischemic neuronal damage (Fig. 6 ).
Neurological side effects
Dextrorphan infusion at all doses in awake rab bits caused pupillary dilatation and tachypnea after Linear regression of percent age area cortical ischemic magnetic resonance imaging (MRI) high signal versus postloading dose plasma free dextrorphan (OX) level for individual rabbits following transient, focal cere bral ischemia. Not all rabbits analyzed for ischemic MRI high signal (Fig. 2) had plasma OX levels measured. All rabbits with OX levels >2,000 ng/ml showed <34% MRI high signal and all those with levels >3,000 ng/ml had <11% MRI high signal. NS, normal sa line controls. (8), left hippocampus versus plasma free dextrorphan (OX) level (C), and left versus right frontal/temporal cortex OX level (0) following varying doses of Lv. OX infusion in anesthetized, ischemic rabbits, Cerebral OX levels were 2-3 times plasma levels. There were no differences in brain levels between ischemic regions (left frontal/temporal cortex, left striatum) versus non ischemic regions (hippocampus, right frontal/temporal cortex). Cerebral areas known to contain higher densities of NMOA receptors (hippocampus, cortex) did not show higher brain levels or differential concentration from plasma compared with cerebral areas with lower density of such receptors (striatum). OX 5 mg/kg (e), OX 10 mg/kg (A.), OX 15 mg/kg (_), the loading dose of drug was finished. Dextrorphan 5 mg/kg caused mild gait ataxia (plasma free dex trorphan levels 272-1,420 ng/ml; cortical brain lev els 1,130--3,795 ng/g). At the two higher doses of dextrorphan (10 and 15 mg/kg) rabbits demon strated progressive gait ataxia, truncal ataxia, and loss of the righting reflex (worse at 15 compared with 10 mg/kg). In these groups plasma dextrorphan levels ranged from 1,730 to 4,005 ng/ml and cortical brain levels from 3,830 to 8,522 ng/g. Loss of pos tural reflexes occurred at plasma dextrorphan levels >2,500 ng/ml. Most of the observed neurologic side effects of dextrorphan resolved completely within 2 h after terminating the infusion. Plasma and brain dextrorphan levels decreased substantially by 2 h after stopping the infusion (plasma levels 326-678 ng/ml; cortical brain levels 1,589-2,598 ng/g). No clinical seizures were observed in any rabbits.
DISCUSSION
The results of this study suggest that systemic treatment with dextrorphan 1 h after the onset of transient focal ischemia can significantly protect J Cereb Blood Flow Metab, Vol, II, No.6, 1991 against the development of neocortical neuronal damage and ischemic MRI injury if adequate plasma levels of dextrorphan are achieved. This neuroprotection does not appear to be simply a threshold effect but rather a dose response with progressively better protection as plasma levels in crease. Kent et al. (1989) have demonstrated that pretreatment with i. v. dextrorphan can attenuate cerebral injury in a rat model of focal ischemia using 10 mg/kg loading dose followed by 10 mg/kg/h for 2 h. Using a global rat ischemia model, Swan and Meldrum (1990) were able to show significant neu ronal protection with a high dose of 54 mg/kg de x trorphan administered i.p. 15 min and 5 h postis chemia, but not with lower doses (2, 6, and 18 mg/ kg). Faden et al. (1989 Faden et al. ( , 1990 found improved neurologic recovery when 10 mg/kg dextrorphan was administered i. v. 30 min after traumatic brain injury, or 15 min following spinal cord injury in rats. The noncompetitive antagonist MK801 also reduces cerebral injury following focal ischemia in several animal models (Gill et al., 1987; Kochhar et al., 1988; Ozyurt et al., 1988; Park et al., 1988) and this response is also dose dependent (Gill et al., 1987) . The lack of protection by even high dose dextror phan on striatal damage has been demonstrated pre viously for dextrorphan and other noncompetitive NMDA antagonists in models of focal cerebral isch emia (Steinberg et aI., 1988 (Steinberg et aI., , 1989a Ozyurt et aI., 1988; Park et aI., 1988) . This may relate to the im portance of dopaminergic excitotoxic mechanisms (Globus et aI., 1987) or to the lack of collateral flow and severity of injury compared with cortex. Dextrorphan plasma levels vary widely among rabbits treated with the same milligram per kilo gram dose, probably due to variable metabolism and excretion of the drug. Dextrorphan is conju gated in the liver primarily to dextrorphan glucuro nide and dextrorphan sulfate, and excreted in the urine and bile (Kamm et aI., 1967; Barnhart, 1980) . Free dextrorphan is concentrated 2-3 times in brain tissue of rabbits compared to plasma, possibly be cause of its lipophilic structure (Benson et aI., 1953; Isbell and Fraser, 1953; Kemp et aI., 1987) . Wills and Martin (1988) also demonstrated high cerebral levels (2-7 times plasma) in rats given i.p. or p. o. dextrorphan. Dextrorphan has been shown to block NMDA-induced excitation in rat spinal cord (Church et aI., 1985) , mouse neuronal culture (Choi et aI., 1987) , and rat or guinea pig brain slices (Cole et al., 1988; Wong et aI., 1988; Aram et aI., 1989) . Dextrorphan also protects against glutamate toxic ity, NMDA-induced damage, and hypoxic injury in neuronal culture (Goldberg et aI., 1987; Choi, 1987; Choi et aI., 1987) . Evidence suggests that dextror phan is a noncompetitive NMDA antagonist acting at the phencyclidine site within the NMDA receptor complex (Javitt et aI., 1987; Lodge et al., 1987) . One explanation for its protective action in vivo is the blockade of neuronal NMDA receptors r = 0.10 P ) 0.50
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Rectal Temperature ( 0 C) against ischemia-induced excitotoxicity. We found a good correlation between brain free dextrorphan levels and plasma levels in the anesthetized rabbit. Dextrorphan also appears to achieve high levels in ischemic cerebral areas. Assuming plasma free dex trorphan levels of 2,500 ng/ml provide �50% neu roprotection against cortical ischemic neuronal damage and ischemic MRI injury ( Figs. 3 and 4) , this would translate to neuroprotective brain free dextrorphan levels of �6,000 ng/g (20 I-LM). Choi et aI. (1987) showed that the median effective dose (EDso) for dextrorphan's protection against gluta mate toxicity and NMDA-induced damage for neu rons in culture is �13-17I-LM. Thus, the in vitro and in vivo dose response characteristics for dextror phan neuroprotective effects are very similar, sug gesting the mechanisms of action in vivo involves antagonism of the NMDA-receptor complex. De spite large differences in density of NMDA recep tors between various brain regions, at least in rat (Quirion et aI., 1981; Monaghan and Cotman, 1985) , we found similar concentrations of dextrorphan in different rabbit cerebral areas (cortex, striatum, thalamus, hippocampus, and cerebellum). How ever, even if dextrorphan must interact with NMDA receptors to mediate its neuroprotective ef fect, brain free dextrorphan levels would not nec essarily reflect NMDA receptor density because dextrorphan may accumulate in cerebral tissue un bound to receptors. It is possible that dextrorphan's ability to atten uate ischemic neuronal damage and ischemic MRI injury is mediated by another mechanism that shows similar dose-response characteristics to in vitro NMDA protection. Dextrorphan has some cal cium antagonist properties and could potentially of-fer neuronal protection in vivo by blocking voltage dependent calcium channels (Carpenter et a!., 1988; Jaffe et a!., 1989) . MK801 is known to affect re gional CBF (Park et a!., 1989; Nehls et a!., 1990; Stevens and Yaksh, 1990) . However, NMDA re ceptors have not been found on cerebral microves sels (Beart et a!., 1988) and it is not clear whether the changes in blood flow following MK801 admin istration are a primary effect or secondary to altered metabolism. Preliminary evidence suggests that MK801 may improve collateral flow to the ischemic penumbra after focal ischemia (Buchan et a!., 1990) , but this effect may be related to NMDA protection of neurons with blood flow coupled to preserved neuronal metabolic activity. It is conceivable that dextrorphan primarily affects collateral flow. Other studies in our laboratory suggest that dextrometh orphan, another noncompetitive antagonist, may prevent the sharp postischemic rise in blood flow within the ischemic core during reperfusion and im prove regional CBF to the ischemic penumbra dur ing the ischemic period (Steinberg et a!., 1990; Lo and Steinberg, 1991) . Dextrorphan might decrease neuronal metabolism, unrelated to NMDA mecha nisms. However, the noncompetitive NMDA antag onist thienylcyclohexylpiperidine does not affect neuronal 2-deoxyglucose activity following focal cerebral ischemia in a rat model where it offers neu roprotection (Duverger et a!., 1987) . Dextrorphan could even interact with an opioid receptor (Gold stein and Naidu, 1990) or the distinct dextrometh orphan receptor (Craviso and Musacchio, 1983a,b) , although dextrorphan has low affinities for both these sites.
The neuroprotective action of MK801 in a gerbil model of cerebral ischemia is dependent upon its ability to induce hypothermia (Buchan and Pulsinelli, 1990 ). Because we controlled rectal tem perature and did not observe differences in temper ature between treatment groups in our study, we believe it unlikely that dextrorphan's protective ef fect was secondary to hypothermia, although we did not measure brain temperature, which may dif fer from rectal temperature . Al though we found a slight increase in the P a02 after occlusion within the 15 mg/kg group compared with the other groups, we do not believe this can explain the neuroprotective effect within this group. Be cause all rabbits had P a02s >400 mm Hg, it is un likely that small differences in the P a02 had any physiological effects. In other experiments demon strating neuroprotection with dextrorphan, we did not find any significant differences in the P a02 be tween groups during occlusion (Steinberg et a!., J Cereb Blood Flow Metab, Vol. 11, No.6, 1991 1989a,b). We are currently using lower concentra tions of inspired O2 to achieve more physiologic values in the P a02 for our animals, and with this protocol have not demonstrated any significant dif ferences in the P a02 to explain dextrorphan's cere broprotective benefit. Finally, although dextror phan has been shown to be an anticonvulsant in several animal and brain slice models (Tortella et aI., 1988; Sepinwall et aI., 1988; Wong et aI., 1988; Aram et a!., 1989) , and might offer neuroprotection through this mechanism, we have not observed clin ical seizures or EEG epileptiform activity in any of our rabbits following ischemia (Steinberg et aI., 1988 (Steinberg et aI., , 1989a .
There are several limitations to the current study. The relatively short reperfusion period of 4.5 h does not allow evaluation of delayed neuronal damage, and it is not known whether the neuroprotective benefit of dextrorphan will be observed at a later time period (e.g., 24 h or 1 week). Our histological evaluation at 5.5 h following the onset of ischemia does not permit precise identification of irreversibly damaged neurons. However, many neuropatholo gists consider areas showing the majority of neu rons meeting our criteria (shrunken, angular, baso philic with dark staining nuclei) suggestive of cere bral infarction (Brierley, 1973; Little et aI., 1974; Garcia and Kamijyo, 1974; Ginsberg et aI., 1979; Tamura et a!., 1980) . MRI appears to be an ex tremely sensitive means of evaluating early cerebral ischemic injury and changes in in vivo Tl and T2 relaxation times are highly correlated with water content measures (Kato et aI., 1985 (Kato et aI., , 1986 Brant Zawadzki et a!., 1986; Horikawa et aI., 1986; Bose et aI., 1988) . However, the MRI T2-weighted high signal intensity areas we quantified may relate to ischemia-induced conformational and structural changes in protein mQlecules with absorption of bound water (Kato et aI., 1986) or alteration in states of water hydration, in addition to free water accumulation. Therefore, we have used the term MRI high signal, rather than ischemic edema, to describe the MRI changes after ischemia. Although formalin perfusion-fixation would be expected to alter MRI relaxation parameters due to membrane changes, protein denaturation, dehydration, and water shifts, we previously showed that in vivo and postfixation images of the same animal (n = 15) using our rabbit model of transient focal ischemia have a high correlation, with 80-85% overlap and no significant differences in relative signal intensity or area of high signal (DeLaPaz et aI., 1991) . Imag ing of the fixed brain provides more rigorous con trol of the in vivo experimental conditions and avoids the problems associated with moving anes thetized rabbits and life support that accompany MRI studies (DeLaPaz et al., 1991) .
Dextrorphan caused severe gait ataxia, truncal ataxia, and loss of the righting reflex in rabbits with plasma levels >2,500 ng/ml. In order to achieve �50% neuroprotection against cortical ischemic neuronal damage or ischemic MRI injury, compa rable plasma levels must be reached. Although the adverse behavioral effects were transient, with al most complete recovery observed within 2 h of ter minating the i. v. infusion, these side effects may limit the potential clinical usefulness of dextror phan, at least for ambulatory patients. For hospital ized patients with an acute stroke, a major neuro logical deficit, or those undergoing surgery carrying high risks of cerebral ischemia, these temporary ad verse effects of dextrorphan might be considered relatively minor or not prohibitive when compared to the potential benefit of the drug. Future studies should examine the width of the "therapeutic window," after which delayed treatment with dex trorphan is ineffective in providing neuroprotec tion. Investigations of regional CBF and metabolic changes following administration of these drugs should be conducted to further elucidate their mechanism of action.
